Program
pemigatinib
Also written as “Pemigatinib”.
Its studies are mostly in Cholangiocarcinoma · Carcinoma, Transitional Cell · Glioblastoma · Neoplasms, Unknown Primary · Myeloproliferative Disorders, led by 3 companies.
Drug pagePemigatinib: every studyAll 46 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Incyte | 131 open or running | phase 3since Aug 29, 2018 | Jan 30, 2015 | Feb 25, 2031phase 2 · NCT07862998 |
| Innovent Biologicsits history only | 20 open or running | phase 2since Jan 20, 2020 | Jan 20, 2020 | none ahead |
| Hoffmann-La Rocheits history only | 10 open or running | phase 2since Apr 5, 2018 | Apr 5, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Incyte only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 30, 2015First study: phase 2 study in Lung NeoplasmsFirst studyNCT02393248 · 201 enrolled · United States, Denmark
- Aug 16, 2016Phase 2 study in Carcinoma, Transitional CellNCT02872714 · 263 enrolled · United States, Belgium, Denmark and more
- Oct 4, 2016Phase 2 study in CholangiocarcinomaNCT02924376 · 147 enrolled · United States, Belgium, France and more
- Jan 4, 2017Phase 2 study in Myeloproliferative DisordersNCT03011372 · 47 enrolled · United States, Austria, Belgium and more
- Jul 27, 2017Phase 1 study in NeoplasmsNCT03235570 · 44 enrolled · Japan
- Dec 9, 2017Named pemigatinibINNProposed as its International Nonproprietary Name in WHO's List 118
- Aug 29, 2018Phase 3 study in CholangiocarcinomaNCT03656536 · 167 enrolled · United States, Austria, Belgium and more
- Jan 28, 2019Phase 2 study in AcrocephalosyndactyliaNCT03822117 · 111 enrolled · United States, Denmark, France and more
- Jun 25, 20192 phase 2 studiesNCT04003623, NCT04003610
- Jun 25, 2021Phase 2 study in Advanced MalignanciesNCT04949191 · 10 enrolled · United States, Denmark, Italy and more
- Feb 14, 20222 phase 2 studiesNCT05253807, NCT05267106
- Oct 2, 2026Phase 2 study in CholangiocarcinomaNCT07862998 · 72 planned
Ahead
- Feb 25, 2031Primary completion: phase 2 study in CholangiocarcinomaNCT07862998
TargetBeta
“An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), ”NCIt, by rule
“Fibroblast growth factor receptor 2 inhibitor; Fibroblast growth factor receptor 3 inhibitor; Fibroblast growth factor receptor 1 inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| nintedanibrule | Boehringer Ingelheim | phase 4 | 76 |
| infigratinibrule | BridgeBio | phase 3 | 17 |
| futibatinibrule | Otsuka | phase 3 | 10 |
Studies
All 13 Incyte leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07862998Cholangiocarcinoma | 2 | Not yet recruiting | Feb 25, 2031 | 72 |
| NCT05267106Glioblastoma · United States, Denmark, France and more | 2 | Terminated | Dec 17, 2024 | 83 |
| NCT05253807Carcinoma, Non-Small-Cell Lung · United States, France, Germany and more | 2 | Completed | Aug 16, 2023 | 8 |
| NCT04949191Advanced Malignancies · United States, Denmark, Italy and more | 2 | Terminated | Apr 11, 2024 | 10 |
| NCT04003610Carcinoma, Transitional Cell · United States, Austria, Belgium and more | 2 | Terminated | Apr 18, 2021 | 7 |
| NCT04003623Neoplasm Metastasis · United States | 2 | Terminated | Jun 12, 2020 | 1 |
| NCT03822117Acrocephalosyndactylia · United States, Denmark, France and more | 2 | Terminated | Mar 29, 2022 | 111 |
| NCT03656536Cholangiocarcinoma · United States, Austria, Belgium and more | 3 | Terminated | Jul 7, 2025 | 167 |
| NCT03235570Neoplasms · Japan | 1 | Completed | Mar 4, 2020 | 44 |
| NCT03011372Myeloproliferative Disorders · United States, Austria, Belgium and more | 2 | Completed | Oct 30, 2024 | 47 |
| NCT02924376Cholangiocarcinoma · United States, Belgium, France and more | 2 | Completed | Feb 1, 2022 | 147 |
| NCT02872714Carcinoma, Transitional Cell · United States, Belgium, Denmark and more | 2 | Completed | Feb 1, 2022 | 263 |
| NCT02393248Lung Neoplasms · United States, Denmark | 2 | Terminated | Dec 17, 2021 | 201 |
How it is read
Names in the registry
- “Pemigatinib”, 15 entries
- “pemigatinib”, 2 entries
Conditions, from the studies’ own filings
- Cholangiocarcinoma, 4 studies
- Carcinoma, Transitional Cell, 2 studies
- Glioblastoma, 1 study
- Neoplasms, Unknown Primary, 1 study
- Myeloproliferative Disorders, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.